Proteasome inhibitors are a type of medication that interfere with the activity of proteasomes.

RANKL inhibitors are drugs that target the RANKL protein, crucial in bone metabolism. The future sees potential applications in treating bone-related disorders and certain cancers.

PD-1 inhibitors are drugs that target the PD-1 protein, crucial for regulating immune responses. The future of PD-1 inhibitors is promising, with potential applications in treating various types of cancer.

Renin inhibitors are drugs that target the enzyme renin, crucial in regulating blood pressure. The future sees potential applications in treating hypertension and other cardiovascular diseases.

PARP inhibitors are drugs targeting the DNA-repairing enzyme PARP1, used in treating ovarian and breast cancer. With ongoing R&D, their future use is expected to expand.

Plasminogen activators inhibitors are substances that regulate clotting by inhibiting enzymes that break down blood clots.

As an important regulator of cAMP signal transduction, the PDE4 family has become a research hotspot for various diseases in recent years.

PD-L1 inhibitors can specifically bind to PD-L1 on tumor cells to inhibit its expression, thereby enabling T cells, whose function has been suppressed, to restore their ability to recognize tumor cells.

NTRK fusion is a driving factor in various adult and pediatric cancers, especially in certain rare tumors like infantile fibrosarcoma and secretory breast cancer, where it is highly enriched. Therefore, the future application prospects of NTRK inhibitors in this area are very promising.

PARP1 inhibitors are a class of drugs that target the PARP1 enzyme, crucial for DNA repair, and are particularly effective against certain cancers.

PDE3 inhibitors are drugs that target the PDE3 enzyme, crucial for regulating cellular signaling pathways.

PCSK9 inhibitors can significantly reduce LDL-C levels, and the development of related drugs is of great importance for the treatment of cardiovascular diseases.